Skip to main content
PMC home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;9(3):469–479. doi: 10.1111/j.1750-3639.1999.tb00536.x

Frequent Co‐Alterations of TP53, p16/CDKN2A, p14 ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines.

Nobuaki Ishii 1, Daniel Maier 2, Adrian Merlo 2, Mitsuhiro Tada 3, Yutaka Sawamura 3, Annie‐Claire Diserens 1, Erwin G Van Meir 1,4,✉
PMCID: PMC8098486  PMID: 10416987

Abstract

In this study we established the simultaneous status of TP53, p16, p14 ARF and PTEN tumor suppressor genes in 34 randomly chosen human glioma cell lines. Nine cell lines (26.4%) harbored mutations or deletions in all four tumor suppressor genes and 22 cell lines (64%) had alterations in at least three. Mutations/deletions were found at the following frequencies: TP53 (76.5%), p14 ARF (64.7%), p16 (64,7%), PTEN (73.5%). Thus, there was a high incidence of alterations in the cellular pathways involving the p53 transcription factor (94.1%), the retinoblastoma protein (64.7%) and the PTEN phosphatase (73.5%) and 91% of cell lines carried mutations in two or more pathways. This provides the first clear genetic evidence that these tumor suppressors participate in biological pathways which are functioning separately/independently in glioma cells. The status of the gene alterations did not correlate with tumorigenicity in immunocompromized mice or any clinical parameters. Although the mutation rate was higher in glioma cell lines than that reported for glioma tissues, the alterations were molecularly representative of those found in adult de novo glioblastoma. This study highlights the importance of developing therapeutic approaches applicable to tumors with a broad range of genetic alterations and also provides an invaluable panel of glioma cell lines to make this possible.

Full Text

The Full Text of this article is available as a PDF (123.9 KB).

References

  • 1. Albertoni M, Daub MD, Arden KC, Viars C, Powell C, Van Meir EG (1998). Genetic instability leads to loss of both p53 alleles in a human glioblastoma. Oncogene. 16: 321–6. [DOI] [PubMed] [Google Scholar]
  • 2. Anker L, Ohgaki H, Ludeke BI, Herrmann HD, Kleihues P, Westphal M (1993). p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer. 55: 982–7. [DOI] [PubMed] [Google Scholar]
  • 3. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJ (1995). Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res. 55: 1351–4. [PubMed] [Google Scholar]
  • 4. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD (1990). Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 50: 8017–22. [PubMed] [Google Scholar]
  • 5. Bigner SH, Mark J, Burger PC, Mahaley MJ, Bullard DE, Muhlbaier LH, Bigner DD (1988). Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 48: 405–11. [PubMed] [Google Scholar]
  • 6. Bilzer T, Stavrou D, Dahme E, Keiditsch E, Burrig KF, Anzil AP, Wechsler W (1991). Morphological, immunocytochemical and growth characteristics of three human glioblastomas established in vitro. Virchows Archiv A, Pathol. Anat & Histopathol. 418: 281–93. [DOI] [PubMed] [Google Scholar]
  • 7. Bostrom J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P, Collins VP, Reifenberger G (1998). Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res. 58: 29–33. [PubMed] [Google Scholar]
  • 8. Burger PC, Scheithauer BW (1993). Tumors of the central nervous system. Armed forces institute of pathology: Washington . [Google Scholar]
  • 9. Chen P, Iavarone A, Fick J, Edwards M, Prados M, Israel MA (1995). Constitutional p53 mutations associated with brain tumors in young adults. Cancer Genet. Cytogenet. 82: 106–15. [DOI] [PubMed] [Google Scholar]
  • 10. Chiariello E, Roz L, Albarosa R, Magnani I, Finocchiaro G (1998). PTEN/MMAC1 mutations in primary glioblastomas and short‐term cultures of malignant gliomas. Oncogene. 16: 541–5. [DOI] [PubMed] [Google Scholar]
  • 11. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyerputtlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A (1998). PTEN mutations in gliomas and glioneuronal tumors. Oncogene. 16: 2259–64. [DOI] [PubMed] [Google Scholar]
  • 12. Epstein F, McCleary EL (1986). Intrinsic brain‐stem tumors of childhood: surgical indications. J. Neurosurg. 64: 11–5. [DOI] [PubMed] [Google Scholar]
  • 13. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher JM, Bron L, Benhattar J, Tada M, Van Meir EG, Estreicher A, Iggo RD (1995). A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA. 92: 3963–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Furnari FB, Lin H, Huang H‐JS, Cavenee WK (1997). Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc. Natl. Acad. Sci. USA. 94: 12479–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Gomi A, Sakai R, Ogawa S, Shinoda S, Hirai H, Masuzawa T (1995). Frequent loss of the cyclin‐dependent kinase‐4 inhibitor gene in human gliomas. Jpn. J. Cancer Res. 86: 342–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Hama S, Sadatomo T, Yoshioka H, Kurisu K, Tahara E, Naruse I, Heike Y, Saijo N (1997). Transformation of human glioma cell lines with the p16 gene inhibits cell proliferation. Anticancer Res. 17: 1933–8. [PubMed] [Google Scholar]
  • 17. He J, Allen JR, Collins VP, Allalunis Turner MJ, Godbout R, Day RS III, James CD (1994). CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 54: 5804–7. [PubMed] [Google Scholar]
  • 18. Hegi ME, zur Hausen A, Ruedi D, Malin G, Kleihues P (1997). Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int. J. Cancer. 73: 57–63. [DOI] [PubMed] [Google Scholar]
  • 19. Ishii N, Sawamura Y, Tada M, Daub DM, Janzer RC, Meagher‐Villemure K, De Tribolet N, Van Meir EG (1998). Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay. Int. J. Cancer. 76: 797–800. [DOI] [PubMed] [Google Scholar]
  • 20. Kamb A, Shattuck‐Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver‐Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon‐Albright LA (1994). Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8: 23–6. [DOI] [PubMed] [Google Scholar]
  • 21. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 91: 649–59. [DOI] [PubMed] [Google Scholar]
  • 22. Kleihues P, Cavenee WK (1997). Pathology and Genetics of Tumors of the Nervous System . International Agency for Research on Cancer: 1st edition Lyon.
  • 23. Li J. Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275: 1943–7. [DOI] [PubMed] [Google Scholar]
  • 24. Liu W, James CD, Frederick L, Alderete BE, Jenkins RB (1997). PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res. 57: 5254–7. [PubMed] [Google Scholar]
  • 24b. Maehama T., Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5‐triphosphate. J Biol Chem. 273: 13375–8. [DOI] [PubMed] [Google Scholar]
  • 25. Maier D, Zhang ZW, Taylor E, Hamou MF, Gratzl O, Van Meir EG, Scott RJ, Merlo A (1998). Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25–26 region as the primary target in low‐grade and high‐grade gliomas. Oncogene. 16: 3331–5. [DOI] [PubMed] [Google Scholar]
  • 26. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D (1995). A novel p16INK4A transcript. Cancer Res. 55: 2995–7. [PubMed] [Google Scholar]
  • 27. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995). 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1: 686–92. [DOI] [PubMed] [Google Scholar]
  • 28. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK (1997). P‐TEN, the tumor suppressor from human chromosome 10q23, is a dual‐specificity phosphatase. Proc. Natl. Acad. Sci. USA. 94: 9052–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, Huang S (1995). Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res. 55: 1941–5. [PubMed] [Google Scholar]
  • 30. Ohgaki H, Schauble B, zur Hausen A, von Ammon K, Kleihues P (1995). Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch. 427: 113–8. [DOI] [PubMed] [Google Scholar]
  • 31. Owens RB, Smith HS, Nelson RW, Springer EL (1976). Epithelial cell cultures from normal and cancerous human tissues. J. Natl. Cancer Inst. 56: 843–9. [DOI] [PubMed] [Google Scholar]
  • 32. Pomerantz J, Schreiberagus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordoncardo C, Depinho RA (1998). The ink4a tumor suppressor gene product, p19(arf), interacts with mdm2 and neutralizes mdm2s inhibition of p53. Cell. 92: 713–23. [DOI] [PubMed] [Google Scholar]
  • 33. Quelle DE, Cheng M, Ashmun RA, Sherr CJ (1997). Cancer‐associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc. Natl. Acad. Sci. USA. 94: 669–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83: 993–1000. [DOI] [PubMed] [Google Scholar]
  • 35. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH (1997). PTEN gene mutations are seen in high‐grade but not in low‐grade gliomas. Cancer Res. 57: 4187–90. [PubMed] [Google Scholar]
  • 36. Rutka JT, Giblin JR, Dougherty DY, Liu HC, McCulloch JR, Bell CW, Stern RS, Wilson CB, Rosenblum ML (1987). Establishment and characterization of five cell lines derived from human malignant gliomas. Acta Neuropathol (Berl). 75: 92–103. [DOI] [PubMed] [Google Scholar]
  • 37. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15: 356–62. [DOI] [PubMed] [Google Scholar]
  • 38. Tabuchi K, Fukuyama K, Mineta T (1992). Cytogenetic diagnosis of brain tumors. Brain and Nerve. 44: 871–9. [PubMed] [Google Scholar]
  • 39. Tada M, Iggo RD, Ishii N, Shinohe Y, Sakuma S, Estreicher A, Sawamura Y, Abe H (1996). Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Int. J. Cancer. 67: 447–50. [DOI] [PubMed] [Google Scholar]
  • 40. Teng DH, Hu R, Lin H, Davis T, IIiev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Bookstein R, Bolen JB, Tavtigian SV, Steck PA (1997). MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 57: 5221–5. [PubMed] [Google Scholar]
  • 41. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, Ohgaki H (1998). PTEN (MMAC1) Mutations Are Frequent in Primary Glioblastomas (de novo) but not in Secondary Glioblastomas. J. Neuropath. Exp. Neur. 57: 684–9. [DOI] [PubMed] [Google Scholar]
  • 42. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang H‐JS, Friedmann T, De Tribolet N, Cavenee WK (1994). Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 54: 649–52. [PubMed] [Google Scholar]
  • 43. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN (1993). Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 3: 19–26. [DOI] [PubMed] [Google Scholar]
  • 44. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R (1997). Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57: 4183–6. [PubMed] [Google Scholar]
  • 45. Waridel F, Estreicher A, Bron L, Flaman JM, Fontolliet C, Monnier P, Frebourg T, Iggo R (1997). Field cancerisation and polyclonal p53 mutation in the upper aero‐digestive tract. Oncogene. 14: 163–9. [DOI] [PubMed] [Google Scholar]
  • 46. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H (1996). Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6: 217–23. [DOI] [PubMed] [Google Scholar]
  • 47. Zhang Y, Xiong Y, Yarbrough WG (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF‐INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92: 725–34. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES